These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 12757410)

  • 21. A Randomized, Double-blind, Placebo-Controlled Crossover Trial of Oxymorphone Hydrochloride and Propoxyphene/Acetaminophen Combination for the Treatment of Neurogenic Claudication Associated With Lumbar Spinal Stenosis.
    Markman JD; Gewandter JS; Frazer ME; Murray NM; Rast SA; McDermott MP; Chowdhry AK; Tomkinson EJ; Pilcher WH; Walter KA; Dworkin RH
    Spine (Phila Pa 1976); 2015 May; 40(10):684-91. PubMed ID: 25705958
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Long-term tolerability and effectiveness of oxymorphone extended release in patients with cancer.
    Slatkin NE; Rhiner MI; Gould EM; Ma T; Ahdieh H
    J Opioid Manag; 2010; 6(3):181-91. PubMed ID: 20642247
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The pain quality response profile of oxymorphone extended release in the treatment of low back pain.
    Gould EM; Jensen MP; Victor TW; Gammaitoni AR; White RE; Galer BS
    Clin J Pain; 2009 Feb; 25(2):116-22. PubMed ID: 19333156
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effectiveness and safety of oral extended-release oxymorphone for the treatment of cancer pain: a pilot study.
    Sloan P; Slatkin N; Ahdieh H
    Support Care Cancer; 2005 Jan; 13(1):57-65. PubMed ID: 15538638
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Titration with oxymorphone extended release to achieve effective long-term pain relief and improve tolerability in opioid-naive patients with moderate to severe pain.
    Rauck R; Ma T; Kerwin R; Ahdieh H
    Pain Med; 2008 Oct; 9(7):777-85. PubMed ID: 18950436
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Oxymorphone: a mature molecule with new life.
    Gimbel JS
    Drugs Today (Barc); 2008 Oct; 44(10):767-82. PubMed ID: 19137130
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Tramadol--Biovail Corporation.
    Drugs R D; 2004; 5(3):182-3. PubMed ID: 15139783
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Analysis of Intensive Care Unit Admission and Sequelae in Patients Intravenously Abusing Extended-Release Oral Oxymorphone.
    Wilson MW; Bonnecaze AK; Dharod A; Miller PJ
    South Med J; 2017 Mar; 110(3):217-222. PubMed ID: 28257549
    [TBL] [Abstract][Full Text] [Related]  

  • 29. EN-3231. Endo Pharmaceuticals.
    Monck N
    Curr Opin Investig Drugs; 2002 Mar; 3(3):459-62. PubMed ID: 12054097
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Oxymorphone Hydrochloride Extended-Release (OPANA®) Associated With Acute Kidney Injury in a Chronic Pain Patient: A Case Report.
    Yatsynovich Y; Souza D; Maroz N
    A A Case Rep; 2017 Dec; 9(11):324-327. PubMed ID: 28786851
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Tramadol extended-release tablets.
    Hair PI; Curran MP; Keam SJ
    Drugs; 2006; 66(15):2017-27; discussion 2028-30. PubMed ID: 17100415
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The meaning of global outcome measures in pain clinical trials: more than just change in pain intensity.
    Jensen MP; Wang W; Potts SL; Gould EM
    Clin J Pain; 2013 Apr; 29(4):289-95. PubMed ID: 23042473
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Review of oral oxymorphone in the management of pain.
    Sloan P
    Ther Clin Risk Manag; 2008 Aug; 4(4):777-87. PubMed ID: 19209260
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Negligible analgesic tolerance seen with extended release oxymorphone: a post hoc analysis of open-label longitudinal data.
    Harden RN; Gagnon CM; Graciosa J; Gould EM
    Pain Med; 2010 Aug; 11(8):1198-208. PubMed ID: 20609129
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy and tolerability of once-daily OROS hydromorphone and twice-daily extended-release oxycodone in patients with chronic, moderate to severe osteoarthritis pain: results of a 6-week, randomized, open-label, noninferiority analysis.
    Hale M; Tudor IC; Khanna S; Thipphawong J
    Clin Ther; 2007 May; 29(5):874-888. PubMed ID: 17697906
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cannabis-based medicines--GW pharmaceuticals: high CBD, high THC, medicinal cannabis--GW pharmaceuticals, THC:CBD.
    Drugs R D; 2003; 4(5):306-9. PubMed ID: 12952500
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Oral oxymorphone for pain management.
    Chamberlin KW; Cottle M; Neville R; Tan J
    Ann Pharmacother; 2007 Jul; 41(7):1144-52. PubMed ID: 17595308
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Changes in prevalence of prescription opioid abuse after introduction of an abuse-deterrent opioid formulation.
    Cassidy TA; DasMahapatra P; Black RA; Wieman MS; Butler SF
    Pain Med; 2014 Mar; 15(3):440-51. PubMed ID: 24330279
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A single dose of liposome-encapsulated oxymorphone or morphine provides long-term analgesia in an animal model of neuropathic pain.
    Smith LJ; Krugner-Higby L; Clark M; Wendland A; Heath TD
    Comp Med; 2003 Jun; 53(3):280-7. PubMed ID: 12868573
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Metformin extended release: metformin gastric retention, metformin GR, metformin XR.
    Drugs R D; 2005; 6(5):316-9. PubMed ID: 16128603
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.